December 06, 2011
Gilead Prices $3.7 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 6, 2011--
$750 millionof 2.40% senior notes maturing in December 2014 $700 millionof 3.05% senior notes maturing in December 2016 $1,250 millionof 4.40% senior notes maturing in December 2021 $1,000 millionof 5.65% senior notes maturing in December 2041
The senior notes are rated A- by Standard & Poor's and Baa1 by Moody's.
The offering is expected to close
Gilead iintends to use the net proceeds from this offering to pay a portion of the cash consideration to purchase all of the outstanding shares of common stock of
Merrill Lynch, Pierce, Fenner & Smith Incorporated
100 West 33rd Street
New York, NY 10001
Attention: Prospectus Department
Barclays Capital Inc.
c/o Broadridge Integrated Prospectus Distribution
1155 Long Island Avenue
Edgewood, NY 11717
An electronic copy of the prospectus supplement and the accompanying base prospectus may also be obtained at no charge at the Securities and Exchange Commission's website at http://www.sec.gov/.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the current market demand for these types of securities and the securities of Gilead, Gilead's ability to consummate the offering in the currently anticipated timeframe or at all and negotiations between Gilead and the underwriters. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Other risks that could impact the offering are described in detail in Gilead's Quarterly Report on Form 10-Q for the period ended
For more information on
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 Investors
Cara Miller, 650-522-1616 Media